Skip to main content

Sunday, September 28, 2025 9/28/2025

GLYCYX MOR, INC.

Address: 330 24TH AVE APT 3 SAN FRANCISCO, CA 94121-2028
County: SAN FRANCISCO
Country: UNITED STATES
UEI: C2B7XPCFTHC7

Group Recipients By:

Issue Date FY Summary

Issue Date FY by OPDIV


	Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Award Number	Award Title	Award Code	Budget Year	OPDIV	Action Date	Action Amount

	Issue Date FY: 2025 ( Subtotal = $1,197,275 )
	2025	2025	GLYCYX MOR, INC.	330 24TH AVE APT 3	SAN FRANCISCO	CA	94121-2028	SAN FRANCISCO	USA	R44CA306565	A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)	000	1	NIH	9/18/2025	$1,197,275
																Subtotal = $1,197,275

	Grand Total All Awards = $1,197,275

Hide

Top